JPWO2021260209A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021260209A5 JPWO2021260209A5 JP2022579796A JP2022579796A JPWO2021260209A5 JP WO2021260209 A5 JPWO2021260209 A5 JP WO2021260209A5 JP 2022579796 A JP2022579796 A JP 2022579796A JP 2022579796 A JP2022579796 A JP 2022579796A JP WO2021260209 A5 JPWO2021260209 A5 JP WO2021260209A5
- Authority
- JP
- Japan
- Prior art keywords
- specific binding
- binding
- specificity
- observed
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009871 nonspecific binding Effects 0.000 description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
Images
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062705434P | 2020-06-26 | 2020-06-26 | |
US62/705,434 | 2020-06-26 | ||
US202062705608P | 2020-07-07 | 2020-07-07 | |
US62/705,608 | 2020-07-07 | ||
EP20205426 | 2020-11-03 | ||
EP20205426.8 | 2020-11-03 | ||
PCT/EP2021/067579 WO2021260209A2 (en) | 2020-06-26 | 2021-06-25 | Ccr8 antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023531989A JP2023531989A (ja) | 2023-07-26 |
JPWO2021260209A5 true JPWO2021260209A5 (ru) | 2024-07-02 |
Family
ID=76553783
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022579795A Pending JP2023531705A (ja) | 2020-06-26 | 2021-06-25 | 抗ccr8抗体療法:バイオマーカー及び併用療法 |
JP2022579798A Pending JP2023531991A (ja) | 2020-06-26 | 2021-06-25 | ケモカイン受容体抗体生成のための硫酸化ペプチド |
JP2022579797A Pending JP2023531990A (ja) | 2020-06-26 | 2021-06-25 | 硫酸化trdモチーフに結合するケモカイン受容体抗体 |
JP2022579796A Pending JP2023531989A (ja) | 2020-06-26 | 2021-06-25 | Ccr8抗体及びその使用 |
JP2022579794A Pending JP2023531988A (ja) | 2020-06-26 | 2021-06-25 | 治療用途のためのccr8抗体 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022579795A Pending JP2023531705A (ja) | 2020-06-26 | 2021-06-25 | 抗ccr8抗体療法:バイオマーカー及び併用療法 |
JP2022579798A Pending JP2023531991A (ja) | 2020-06-26 | 2021-06-25 | ケモカイン受容体抗体生成のための硫酸化ペプチド |
JP2022579797A Pending JP2023531990A (ja) | 2020-06-26 | 2021-06-25 | 硫酸化trdモチーフに結合するケモカイン受容体抗体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022579794A Pending JP2023531988A (ja) | 2020-06-26 | 2021-06-25 | 治療用途のためのccr8抗体 |
Country Status (14)
Country | Link |
---|---|
US (3) | US20230250178A1 (ru) |
EP (5) | EP4172202A2 (ru) |
JP (5) | JP2023531705A (ru) |
KR (2) | KR20230028780A (ru) |
CN (6) | CN117653725A (ru) |
AU (2) | AU2021295721A1 (ru) |
BR (2) | BR112022026208A2 (ru) |
CA (3) | CA3188138A1 (ru) |
CL (1) | CL2022003747A1 (ru) |
IL (2) | IL298896A (ru) |
MX (2) | MX2022015968A (ru) |
PE (1) | PE20231200A1 (ru) |
TW (1) | TW202216771A (ru) |
WO (5) | WO2021260209A2 (ru) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
CN115052892B (zh) | 2020-10-16 | 2023-07-07 | 礼新医药科技(上海)有限公司 | 抗ccr8单克隆抗体及其用途 |
JPWO2022211046A1 (ru) | 2021-03-31 | 2022-10-06 | ||
EP4347655A1 (en) * | 2021-06-04 | 2024-04-10 | Amgen Inc. | Anti-ccr8 antibodies and uses thereof |
TW202321304A (zh) | 2021-07-27 | 2023-06-01 | 美商艾伯維有限公司 | 抗ccr8抗體 |
KR20240046533A (ko) * | 2021-08-20 | 2024-04-09 | 하이파이바이오 인코퍼레이티드 | 항-ccr8 항체 및 그것의 용도 |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
TW202342533A (zh) * | 2021-12-02 | 2023-11-01 | 中國大陸商再鼎醫藥(上海)有限公司 | Ccr8抗原結合單元及其用途 |
AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2023230473A1 (en) | 2022-05-24 | 2023-11-30 | Bristol-Myers Squibb Company | Antibodies that bind to human ccr8 |
WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
WO2023245074A2 (en) * | 2022-06-14 | 2023-12-21 | Purdue Research Foundation | Car-expressing pluripotent stem cell-derived neutrophils loaded with drug nanoparticles and uses thereof |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024026400A2 (en) * | 2022-07-27 | 2024-02-01 | Varian Medical Systems, Inc. | Therapeutic combinations of titr effectors with radiation therapy |
WO2024052517A2 (en) * | 2022-09-09 | 2024-03-14 | Bayer Aktiengesellschaft | Medical use of ccr8 antibodies and dosing schedule |
WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
WO2024059909A1 (en) * | 2022-09-21 | 2024-03-28 | Monash University | Anti-ccr8 antibodies |
WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
WO2024077239A1 (en) * | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
WO2024088346A1 (en) * | 2022-10-28 | 2024-05-02 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-ccr8 antibodies and uses thereof |
WO2024097741A1 (en) * | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations |
WO2024109657A1 (zh) * | 2022-11-22 | 2024-05-30 | 上海宏成药业有限公司 | 抗ccr8抗体及其用途 |
CN117285627B (zh) * | 2023-09-06 | 2024-06-14 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US6329510B1 (en) * | 1999-01-29 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-CCR1 antibodies and methods of use therefor |
AU2001250412A1 (en) | 2000-03-31 | 2001-10-08 | Ipf Pharmaceuticals Gmbh | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
WO2003096020A2 (en) * | 2002-05-13 | 2003-11-20 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8) |
US20080260744A1 (en) * | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
US20050069955A1 (en) * | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
US20050266009A1 (en) * | 2003-06-30 | 2005-12-01 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
CA3052445C (en) | 2004-07-10 | 2023-08-22 | Kerry S. Campbell | Genetically modified human natural killer cell lines |
WO2007044756A2 (en) | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
WO2008112640A2 (en) | 2007-03-09 | 2008-09-18 | Sinomab Bioscience Limited | Construction and use of a functionally human antibody library with maximized repertoire diversity |
GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
MY160680A (en) | 2009-09-22 | 2017-03-15 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
US20150370960A1 (en) * | 2014-03-27 | 2015-12-24 | Massachusetts Institute Of Technology | Water-soluble membrane proteins and methods for the preparation and use thereof |
US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
CN107074945B (zh) * | 2014-05-27 | 2021-08-24 | 中央研究院 | 增进抗体功效的通用糖型的组合物及方法 |
MA41176A (fr) | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
CA2994214C (en) * | 2015-08-10 | 2024-03-12 | Pepmab B.V. | Humanized anti-ccr7 receptor antibodies |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
JP7358047B2 (ja) | 2016-05-16 | 2023-10-10 | チェックマブ エス.アール.エル. | 腫瘍浸潤制御性t細胞において選択的に脱制御されたマーカー |
US20170360932A1 (en) * | 2016-06-17 | 2017-12-21 | Varian Medical Systems, Inc. | Immune modulators in combination with radiation treatment |
WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
HUE054316T2 (hu) | 2017-03-29 | 2021-08-30 | Shionogi & Co | Gyógyászati készítmény rák kezelésére |
JP2021512103A (ja) | 2018-01-31 | 2021-05-13 | バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft | Nampt阻害剤を含む抗体薬物複合体(adcs) |
WO2019157098A1 (en) | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
WO2019243159A1 (de) | 2018-06-18 | 2019-12-26 | Bayer Aktiengesellschaft | Gegen cxcr5 gerichtete binder-wirkstoff-konjugate mit enzymatisch spaltbaren linkern und verbessertem wirkungsprofil |
CN110835374A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8×ctla-4双特异性抗体及其应用 |
WO2020102240A1 (en) | 2018-11-13 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
US20220064312A1 (en) * | 2018-12-27 | 2022-03-03 | Shionogi & Co., Ltd. | Novel Anti-CCR8 Antibody |
IL294330A (en) * | 2020-01-06 | 2022-08-01 | Vaccinex Inc | Anti-ccr8 antibodies and their uses |
US11692038B2 (en) * | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
EP4114862A4 (en) | 2020-03-05 | 2024-07-03 | Memorial Sloan Kettering Cancer Center | ANTI-CCR8 ACTIVE AGENTS |
TW202202521A (zh) | 2020-03-23 | 2022-01-16 | 美商必治妥美雅史谷比公司 | 用於治療癌症之抗ccr8抗體 |
US20230256092A1 (en) | 2020-06-30 | 2023-08-17 | Shionogi & Co., Ltd. | Combined use of anti-ccr8 antibody and chemotherapeutic agent |
WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
WO2022000443A1 (en) | 2020-07-03 | 2022-01-06 | Nanjing Immunophage Biotech Co., Ltd. | Methods and compositions for targeting tregs using ccr8 inhibitors |
US20230320332A1 (en) | 2020-09-11 | 2023-10-12 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric ccr8 |
-
2021
- 2021-06-24 TW TW110123093A patent/TW202216771A/zh unknown
- 2021-06-25 IL IL298896A patent/IL298896A/en unknown
- 2021-06-25 CN CN202311684511.5A patent/CN117653725A/zh active Pending
- 2021-06-25 WO PCT/EP2021/067579 patent/WO2021260209A2/en unknown
- 2021-06-25 KR KR1020237002375A patent/KR20230028780A/ko unknown
- 2021-06-25 CA CA3188138A patent/CA3188138A1/en active Pending
- 2021-06-25 MX MX2022015968A patent/MX2022015968A/es unknown
- 2021-06-25 JP JP2022579795A patent/JP2023531705A/ja active Pending
- 2021-06-25 AU AU2021295721A patent/AU2021295721A1/en active Pending
- 2021-06-25 CN CN202180047298.XA patent/CN116096749A/zh active Pending
- 2021-06-25 MX MX2022015954A patent/MX2022015954A/es unknown
- 2021-06-25 IL IL298910A patent/IL298910A/en unknown
- 2021-06-25 CA CA3188142A patent/CA3188142A1/en active Pending
- 2021-06-25 CN CN202180047293.7A patent/CN116096748A/zh active Pending
- 2021-06-25 US US18/003,118 patent/US20230250178A1/en active Pending
- 2021-06-25 WO PCT/EP2021/067574 patent/WO2021260206A2/en unknown
- 2021-06-25 EP EP21736313.4A patent/EP4172202A2/en active Pending
- 2021-06-25 BR BR112022026208A patent/BR112022026208A2/pt unknown
- 2021-06-25 CN CN202180047296.0A patent/CN116096395A/zh active Pending
- 2021-06-25 KR KR1020237002373A patent/KR20230028453A/ko unknown
- 2021-06-25 WO PCT/EP2021/067580 patent/WO2021260210A2/en unknown
- 2021-06-25 CA CA3188146A patent/CA3188146A1/en active Pending
- 2021-06-25 CN CN202180047299.4A patent/CN116096750A/zh active Pending
- 2021-06-25 US US17/358,841 patent/US11427640B1/en active Active
- 2021-06-25 EP EP21734019.9A patent/EP4172204A2/en active Pending
- 2021-06-25 BR BR112022026121A patent/BR112022026121A2/pt unknown
- 2021-06-25 JP JP2022579798A patent/JP2023531991A/ja active Pending
- 2021-06-25 JP JP2022579797A patent/JP2023531990A/ja active Pending
- 2021-06-25 JP JP2022579796A patent/JP2023531989A/ja active Pending
- 2021-06-25 JP JP2022579794A patent/JP2023531988A/ja active Pending
- 2021-06-25 PE PE2022003003A patent/PE20231200A1/es unknown
- 2021-06-25 EP EP21736311.8A patent/EP4171601A2/en active Pending
- 2021-06-25 EP EP21736310.0A patent/EP4172201A2/en active Pending
- 2021-06-25 CN CN202180047358.8A patent/CN116234825A/zh active Pending
- 2021-06-25 WO PCT/EP2021/067578 patent/WO2021260208A2/en unknown
- 2021-06-25 WO PCT/EP2021/067504 patent/WO2021152186A2/en active Application Filing
- 2021-06-25 EP EP21736312.6A patent/EP4171602A2/en active Pending
- 2021-06-25 AU AU2021212327A patent/AU2021212327A1/en active Pending
-
2022
- 2022-04-22 US US17/727,220 patent/US20220363768A1/en active Pending
- 2022-12-23 CL CL2022003747A patent/CL2022003747A1/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2021260206A5 (ru) | ||
JPWO2021260209A5 (ru) | ||
JPWO2021260210A5 (ru) | ||
JPWO2021152186A5 (ru) | ||
JPWO2021260208A5 (ru) | ||
Dudai et al. | Purification by affinity chromatography of acetylcholinesterase from electric organ tissue of electric eel subsequent to tryptic treatment | |
Liao et al. | High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma | |
JP2540508B2 (ja) | 化学反応を触媒する方法 | |
CA2329776A1 (en) | Antibody against lar phosphatase subunit | |
BR0307216A (pt) | Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma) | |
CA2323096A1 (en) | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen | |
NO984136L (no) | Humanisert kimµrt antistoffmolekyl for bruk som dianostikum, og diagnostisk preparat omfattende et slikt antistoffmolekyl | |
ATE342282T1 (de) | Humane monoklonale antikörper gegen prostata spezifisches membranantigen | |
BR0314814A (pt) | Variantes otimizadas de fc e métodos para sua geração | |
GB2414732A (en) | Human antibodies specific for interleukin 15 (IL-15) | |
DK180380A (da) | Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf | |
DE602005018028D1 (de) | Monoklonale antikörper mit spezifität für fetale erythroidzellen | |
WO2004087758A3 (en) | Il 13 receptor alpha 2 antibody and methods of use | |
NO20073797L (no) | Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) | |
EA200800812A1 (ru) | Композиции антитела против cd3 | |
JP2013509878A5 (ru) | ||
ATE427488T1 (de) | Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion | |
JP2008545000A5 (ru) | ||
NO965239D0 (no) | Monoklonalt antistoff mot CD44v6 | |
WO2003038062A3 (en) | Generation of use of tc1 and tc2 cells |